Description: Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
Home Page: www.xencor.com
XNCR Technical Analysis
111 West Lemon Avenue
Monrovia,
CA
91016
United States
Phone:
626 305 5900
Officers
Name | Title |
---|---|
Dr. Bassil I. Dahiyat Ph.D. | Co-Founder, CEO, Pres & Director |
Mr. John J. Kuch | Sr. VP & CFO |
Dr. John R. Desjarlais | Sr. VP of Research & Chief Scientific Officer |
Ms. Celia E. Eckert J.D. | Sr. VP, Gen. Counsel & Corp. Sec. |
Dr. Allen S. Yang M.D., Ph.D. | Sr. VP & Chief Medical Officer |
Mr. Charles Liles | Associate Director and Head of Corp. Communications & Investor Relations |
Ms. Jennifer Sandoz | VP of HR |
Dr. Jeremy Grunstein Ph.D. | Sr. VP of Bus. Devel. |
Mr. Kirk Rosemark RAC | Sr. VP of Regulatory Affairs & Quality Assurance |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 55.0408 |
Price-to-Book MRQ: | 2.3648 |
Price-to-Sales TTM: | 5.567 |
IPO Date: | 2013-12-03 |
Fiscal Year End: | December |
Full Time Employees: | 254 |